Speaker(s): 

Alexis V. Fanshier, PharmD, PGY-2 Hematology/Oncology Pharmacy Resident, Geisinger - has nothing to disclose.

Moderator(s): 

Christopher DeFrancesco, PharmD, Clinical Pharmacist / Asst Pharmacy Residency Program Director Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Describe relapse/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).

2. Summarize DLBCL R/R transplant-ineligible treatment paradigms.

3. Interpret SUNMO data for mosunetuzumab + polatuzumab in transplant-ineligible R/R large B-cell lymphoma (LBCL)

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Christopher DeFrancesco PharmD, RPH; Anil Singh MD; Roop Parlapalli, MD, FHM, FACP; Carolyn Chilewshi, PA-C; Emilie Detweiler, PharmD, RPh; Alexa Kerecman, CRNP; John Sacino, CPhT, and Miranda Steigler, PharmD, RPh have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.